NDA 214679 · Azurity
Eprontia
Topiramate · Oral
Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Nov 5, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
302
82 Phase 3, 10 recruiting
FAERS reports
50,531
38,698 serious, 5,656 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 13, 2025.
EPRONTIA is indicated for: Epilepsy: Initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older ( 1.2 ). Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ). 1.1 Monotherapy Epilepsy EPRONTIA is indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.2 Adjunctive Therapy Epilepsy EPRONTIA is indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older. 1.3 Migraine EPRONTIA is indicated for the preventive treatment of migraine in patients 12 years of age and older.
Mechanism: The precise mechanisms by which topiramate exerts its anticonvulsant and preventive migraine effects are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate's efficacy for epilepsy and the preventive treatment of migraine. Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- EPRONTIA · TOPIRAMATE 25MG/ML · SOLUTION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Topiramate" as an intervention, any sponsor and status, largest first.
- A Toolbox Approach to Obesity Treatment in Primary CarePivotal-lookingCompleted
Denver Health and Hospital AuthorityAcademic, hospital or other
NCT01922934 · 4,730 participants · Start Jan 2014 · Primary completion Aug 2016
Drug: Obesity pharmacotherapy · For: Obesity
Sites: Denver, Colorado
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- Efficacy and Safety of DanzhenStatus unknown
Xijing HospitalAcademic, hospital or other
NCT02645370 · 3,300 participants (planned) · Start Feb 2016 · Primary completion Jul 2017
Drug: Danzhen; Topiramate · For: Migraine
Sites: Xi’an, China
- Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid ConditionsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00553787 · 2,487 participants · Start Nov 2007 · Primary completion Jun 2009
Drug: VI-0521; VI-0521 and 1 more · For: Obesity; Type 2 Diabetes
Sites: Birmingham, Alabama; Ridgefield, Connecticut; New York, New York · 6 sites in all
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyPivotal-lookingRecruiting
Mayo ClinicAcademic, hospital or other
NCT06972056 · 1,335 participants (planned) · Start Jul 9, 2025 · Primary completion Mar 1, 2029
Drug: Atogepant 60 mg; Propranolol 160 mg and 1 more · For: Migraine
Sites: Hazel Green, Alabama; Flagstaff, Arizona; Phoenix, Arizona · 39 sites in all
- A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With ObesityPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00236639 · 1,293 participants · Start Jul 2000
Drug: topiramate · For: Obesity
- Study of VI-0521 Compared to Placebo in Treatment of Obesity in AdultsPivotal-lookingCompleted
VIVUS LLCIndustry
NCT00554216 · 1,267 participants · Start Nov 2007 · Primary completion May 2009
Drug: VI-0521; VI-0521 and 1 more · For: Obesity
Sites: San Diego, California; Ridgefield, Connecticut; Durham, North Carolina · 5 sites in all
- A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With EpilepsyPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00236717 · 865 participants · Start Sep 1997
Drug: Topiramate; Carbamazepine; Valproate · For: Epilepsy; Seizures
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective7,042
- off label use5,694
- headache3,683
- nausea3,328
- fatigue3,196
- product use in unapproved indication2,623
- pain2,574
- migraine2,544
- dizziness2,419
- seizure2,273
- condition aggravated2,215
- diarrhoea2,210
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 139 |
| 2005 | 254 |
| 2006 | 207 |
| 2007 | 196 |
| 2008 | 383 |
| 2009 | 775 |
| 2010 | 941 |
| 2011 | 1,213 |
| 2012 | 1,395 |
| 2013 | 1,214 |
| 2014 | 1,551 |
| 2015 | 2,420 |
| 2016 | 2,928 |
| 2017 | 2,678 |
| 2018 | 3,542 |
| 2019 | 3,947 |
| 2020 | 3,671 |
| 2021 | 3,717 |
| 2022 | 3,597 |
| 2023 | 3,911 |
| 2024 | 4,561 |
| 2025 | 4,463 |
| 2026 | 2,823 |
Recalls
1 FDA enforcement reports for this application.
Dec 8, 2023 · Class III · Terminated
Failed Impurities/Degradation Specifications: Out of specification Impurity C (4,5-desisopropylidene topiramate) result observed during routine stability testing at 18 months.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Eprontia (Topiramate)
2024 spending
$896K
Beneficiaries
235
1,364 claims
Per beneficiary
$3,811
$1.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $174,619 |
| 2023 | $522,146 |
| 2024 | $895,691 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis.
Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. · J Headache Pain 2023 · Systematic Review, Network Meta-Analysis
- Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Wang Y, Hao Q, et al. · Lancet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
Giri S, Tronvik E, Linde M, et al. · Cephalalgia 2023 · Meta-Analysis, Systematic Review
- Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis.
Chan B, Kondo K, Freeman M, et al. · J Gen Intern Med 2019 · Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S.
- Updated Canadian Headache Society Migraine Prevention Guideline with Systematic Review and Meta-analysis.
Medrea I, Cooper P, Lagman-Bartolome AM, et al. · Can J Neurol Sci 2025 · Systematic Review, Meta-Analysis
- Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis.
Brownley KA, Berkman ND, Peat CM, et al. · Ann Intern Med 2016 · Meta-Analysis, Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.